Meeting
2024 ASCO Annual Meeting
Fruquintinib plus capecitabine versus capecitabine as first-line maintenance treatment of metastatic colorectal cancer (mCRC): Update results from the randomized, controlled, phase Ib/II study.
Authors
Wenhua Li
Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China
Wenhua Li , Jinjia Chang , Chenchen Wang , Junjie Peng
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Colorectal and Anal
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer–Advanced Disease
Clinical Trial Registration Number
NCT05451719
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr 3567)
DOI
10.1200/JCO.2024.42.16_suppl.3567
Abstract #
3567
Poster Bd #
230
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Gastrointestinal Cancers Symposium
BREAKWATER: Randomized phase 3 study of encorafenib (enco) + cetuximab (cet) ± chemotherapy for first-line treatment (tx) of BRAF V600E-mutant (BRAFV600) metastatic colorectal cancer (mCRC).
First Author: Scott Kopetz
Poster
2021 ASCO Annual Meeting
BREAKWATER: Randomized phase 3 study of encorafenib (enco) + cetuximab (cetux) ± chemotherapy for first-line (1L) treatment (tx) of BRAF V600E-mutant (BRAFV600E) metastatic colorectal cancer (mCRC).
First Author: Scott Kopetz
Poster
2023 ASCO Gastrointestinal Cancers Symposium
The efficacy of capecitabine as a salvage treatment in metastatic colorectal cancer after prior 5-fluorouracil–included chemotherapies.
First Author: Jae Yeon Jang
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Effectiveness of biologic agents among Hispanics in the US with metastatic colorectal cancer.
First Author: Riya Jayesh Patel